Naval G. Daver, MD

Naval G. Daver, MD, discusses persisting gaps in the treatment of patients with relapsed/refractory higher-risk myelodysplastic syndromes.

Naval G. Daver, MD, discusses early efficacy and safety data for bexmarilimab plus azacitidine in patients with higher-risk myelodysplastic syndrome.

Naval Daver, MD, discusses the evolving role of menin inhibition in acute myeloid leukemia and emerging data with revumenib.

Naval G. Daver, MD, highlights the efficacy of revumenib for the treatment of patients with NPM1-mutant relapsed/refractory acute myeloid leukemia.

Naval G. Daver, MD, discusses updated findings from a phase 1/2 study of the menin-MLL inhibitor DSP-5336 in relapsed/refractory acute leukemias.